

AGENDA

***Uniform Formulary Beneficiary Advisory Panel (UF BAP)
For the November 2024 Department of Defense Pharmacy and Therapeutics
Committee Meeting
December 18, 2024 at 10:00 AM Eastern Daylight Time***

Virtual Meeting

- **General session starts at 10:00 AM Eastern Daylight Time (Administrative meeting preceding)**

- **Roll Call**

- **Therapeutic Class Reviews**

Members of the Defense Health Agency (DHA) Pharmacy Operations Division (POD) Formulary Management Branch (FMB) will present relative clinical and cost-effective analyses along with the Department of Defense (DoD) Pharmacy & Therapeutics Committee (P&T) recommendations for the Uniform Formulary (UF) and any recommended complete exclusion candidates.

The DoD P&T Committee made recommendations for the following drugs/drug classes during the November 2024 meeting.

- **Drug Class Reviews**

- *Targeted Immunomodulatory Biologics (TIB) Class*
 - *Interleukin (IL)-17 Inhibitor Subclass*
 - *IL-23 Inhibitor Subclass*
- *Migraine Agents Class*
 - *Oral Calcitonin Gene-Related Peptide (CGRP) Subclass*
- *Insulins Class Clinical Effectiveness Review*
 - *Rapid-Acting Insulin Analogs Subclass*
 - *Short-Acting, Intermediate-Acting, and Combination Insulin Analogs Subclass*

- **Newly Approved Drugs per 32 CFR 199.21(g)(5)**

- *aprocitentan (Tryvio)—Anti-Hypertensive Agents: Endothelin Receptor Agonists*
- *carbidopa/levodopa extended release (XR) capsules (Crexont)—Parkinson's Agents*
- *clobetasol 0.05% ophthalmic suspension (no brand name)—Ophthalmic Agents*
- *clonidine XR 0.1 mg/mL oral suspension (Onyda XR)—Attention Deficit Hyperactivity Disorder Agents: Non-stimulants*
- *ensifentrine nebulizer inhalation solution (Ohtuvayre)—Pulmonary-2 Agents:*

Chronic Obstructive Pulmonary Disease

- *epinephrine nasal spray (Neffy)—Respiratory Agents*
- *lazertinib (Lazcluze)—Oncological Agents: Epidermal Growth Factor (EGFR) plus Non-Small Cell Lung Cancer (NSCLC)*
- *lebrikizumab-lbkz (Ebglyss)—Atopy Agents*
- *levacetylleucine (Aqneursa)—Neurological Agents*
- *nemolizumab-ilto (Nemluvio)—TIBs: Miscellaneous Interleukins*
- *norethindrone acetate/ethinyl estradiol orally dissolving tablets (ODT) (Femlyv)—Contraceptive Agents: Monophasics with 20 mcg estrogen*
- *palopegteriparatide (Yorvipath)—Osteoporosis Agents*
- *seladelpar (Livdelzi)—Gastrointestinal-2 Agents*
- *sofpironium 12.45% topical gel pump (Sofdra)—Antiperspirants*
- *tirzepatide vial (Zepbound vials)—Weight Loss Agents*
- *vadadustat (Vafseo)—Hematological Agents: Red Blood Cell (RBC) Stimulants Erythropoietin Agents*
- *vigabatrin 100 mg/mL oral solution (Vigafyde) —Anticonvulsant and Antimania Agents*
- *vorasidenib (Vorranigo)—Oncological Agents*
- *xanomeline/trospium (Cobenfy) —Antipsychotic Agents: Atypicals*

➤ **Utilization Management Issues**

- **PA Criteria—Manual PA Criteria for Newly Approved Drugs Not Subject to 32 CFR 199.21(g)(5)**
 - *Oncological Agents—Renal Cell Carcinoma: everolimus tablets (Torpenz)*
 - *Skeletal Muscle Relaxants and Combinations: methocarbamol 1,000 mg tablets (generic, Tanlor)*
 - *Antiemetic-Antivertigo Agents: ondansetron 16 mg ODT*
- **PA Criteria—Updated PA Criteria for New FDA-Approved Indications**
 - *Oncological Agents—repotrectinib (Augtyro)*
 - *Oncological Agents: Lung Cancer—adagrasib (Krazati)*
 - *Oncological Agents: Lung Cancer—selpercatinib (Retevmo)*
 - *Oncological Agents: Ovarian Cancer—olaparib (Lynparza)*
 - *Psoriasis Agents—roflumilast 0.15% cream (Zoryve)*
 - *Atopy Agents—dupilumab (Dupixent)*

- *Atopy Agents—benralizumab (Fasenra Pen)*
- *TIBs: Non-Tumor Necrosis Factor Inhibitors (TNFs)—apremilast (Otezla)*
- *TIBs—certolizumab (Cimzia)*
- *Anticonvulsant Antimania Agents Miscellaneous—lacosamide ER (Motpoly XR)*
- *Immunological Miscellaneous Agents—peanut (*Arachis hypogaea*) allergen powder-dnfp (Palforzia)*
- **PA Criteria—Updated PA Criteria for Reasons Other Than New Indications**
 - *Antipsychotic Agents: Atypical—pimavanserin (Nuplazid)*
 - *Antifungals—oteseconazole (Vivjoa)*
 - *Hematological Agents—iptacopan (Fabhalta)*
 - *Osteoporosis Agents: Parathyroid Hormone (PTH) Analogs—teriparatide (Forteo, Bonsity)*
 - *Gynecological Agents Miscellaneous—fezolinetant (Veozah)*
 - *Pancreatic Enzyme Replacement Therapy (PERT)—pancrelipase (Zenpep)*
- **PA Updates for the Antilipidemic-1s Class**
 - *Non-Statins and Combinations Subclass—bempedoic acid (Nexletol), bempedoic acid/ezetimibe (Nexlizet)*
 - *Proprotein Convertase Subtilisin/Kexin Type-9 (PCK-9) Inhibitors Subclass—evolocumab (Repatha)*
- **Re-Evaluation of Non-Formulary Generics—Acne Agents: Topical Acne and Rosacea**
 - *adapalene/benzoyl peroxide 0.1/2.5% gel pump (Epiduo generics)*
 - *adapalene/benzoyl peroxide 0.3/2.5% gel pump (Epiduo Forte generics)*
 - *clindamycin/BP 1.2/2.5% gel (Acanya generics)*

➤ **Panel Discussions**

The UF BAP members will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will concur or non-concur on the recommendations of the DoD P&T Committee concerning the establishment of the UF and subsequent recommended changes. The Panel will provide comments on their vote as directed by the Panel Chairman. Comments to the Director, DHA, or their designee will be considered before making a final UF decision.